Evidence map›Paper›PMID 27729313›Full record

ArticleCancer discovery2016

Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation.

David S Hong, Van K Morris, Badi El Osta, Alexey V Sorokin, Filip Janku, Siqing Fu, Michael J Overman, Sarina Piha-Paul, Vivek Subbiah, Bryan Kee and 11 more

Open access · greenAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer discovery, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 135 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
135citing papers in PubMed, 4 pooled it
12.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

135 citing papers in PubMed, 4 syntheses or guidelines pooled it, 217 citations in OpenAlex.

  1. Targeted therapy in advancedBMJ (Clinical research ed.) · 2025
    Pooled it
  2. Pooled it
  3. NCCN Guidelines Insights: Colon Cancer, Version 2.2018.Journal of the National Comprehensive Cancer Network : JNCCN · 2018
    Guideline
  4. Pooled it
  5. Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406).Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021
    Trial
  6. Encorafenib Plus Cetuximab as a New Standard of Care for Previously TreatedJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021
    Trial
  7. Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients WithJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2019
    Trial
  8. Trial
  9. Trial
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article

75 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 5 institutions in 2 countries.

David S HongDepartment of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas. dshong@mdanderson.org.
Van K MorrisDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Badi El OstaDepartment of Hematology and Medical Oncology, Atlanta Veterans Affairs Medical Center, Emory University School of Medicine, Atlanta, Georgia.
Alexey V SorokinDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Filip JankuDepartment of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Siqing FuDepartment of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Michael J OvermanDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Sarina Piha-PaulDepartment of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Vivek SubbiahDepartment of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Bryan KeeDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Apostolia M TsimberidouDepartment of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
David FogelmanDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jorge BellidoDepartment of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Imad ShureiqiDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Helen HuangDepartment of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Johnique AtkinsDepartment of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Gabi TarcicNovellusDx, Jerusalem, Israel.
Nicolas SommerGenentech, San Francisco, California.
Richard LanmanGuardant Health, Redwood City, California.
Funda Meric-BernstamDepartment of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Scott KopetzDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
The University of Texas MD Anderson Cancer Center · USAcentech (United States) · USEmory University · USGuardant (United States) · USMarvell (Israel) · IL

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Paul Calabresi Clinical Oncology AwardK12CA088084 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI David S. Hong, Scott Kopetz · 2000 to 2026
$14.0M
Center for Clinical and Translational Sciences (CCTS)KL2TR000370 · NCATS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI MCPHERSON, DAVID D · 2012 to 2016
$4.3M
Tumor Heterogeneity and Acquired Resistance to EGFR InhibitionR01CA184843 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HAMILTON, STANLEY R., KOPETZ, SCOTT · 2015 to 2019
$3.2M
Therapeutic Strategies for Patients With BRAF Mutant Colorectal CancerR01CA187238 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HONG, DAVID S., KOPETZ, SCOTT · 2014 to 2018
$1.7M
Stress Signaling Pathways and Resistance in Colorectal CancerR01CA172670 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KOPETZ, SCOTT · 2013 to 2017
$1.6M
NCATS NIH HHS KL2 TR000370NCI NIH HHS K12 CA088084NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA172670NCI NIH HHS R01 CA184843NCI NIH HHS R01 CA187238
6 · The paper itself

Abstract

In vitro, EGFR inhibition, combined with the BRAF inhibitor vemurafenib, causes synergistic cytotoxicity for BRAF SIGNIFICANCE: Vemurafenib, in combination with irinotecan and cetuximab, was well tolerated in patients with refractory, BRAF-mutated metastatic colorectal cancer, and both survival outcomes and response rates exceeded prior reports for vemurafenib and for irinotecan plus cetuximab in BRAF

Indexed as

AnimalsAntineoplastic Combined Chemotherapy ProtocolsCamptothecinCell Line, TumorCetuximabColorectal NeoplasmsDisease-Free SurvivalDrug Administration ScheduleFemaleHumansIndolesIrinotecanMaleMiceMutationNeoplasm MetastasisBRAF protein, humanCamptothecinCetuximabIndolesIrinotecanProto-Oncogene Proteins B-rafSulfonamidesVemurafenib

Identifiers

PMID27729313
PMCPMC5562357
OpenAlexW2530590137

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.